Our top pick for
Athira Pharma, Inc is a biotechnology business based in the US. Athira Pharma shares (ATHA) are listed on the NASDAQ and all prices are listed in US Dollars.
|52-week range||USD$15.79 - USD$34.79|
|50-day moving average||USD$23.7365|
|200-day moving average||USD$23.0587|
|Wall St. target price||USD$44.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$812.2 million|
TTM: trailing 12 months
There are currently 807,897 Athira Pharma shares held short by investors – that's known as Athira Pharma's "short interest". This figure is 13.8% down from 937,207 last month.
There are a few different ways that this level of interest in shorting Athira Pharma shares can be evaluated.
Athira Pharma's "short interest ratio" (SIR) is the quantity of Athira Pharma shares currently shorted divided by the average quantity of Athira Pharma shares traded daily (recently around 453874.71910112). Athira Pharma's SIR currently stands at 1.78. In other words for every 100,000 Athira Pharma shares traded daily on the market, roughly 1780 shares are currently held short.
To gain some more context, you can compare Athira Pharma's short interest ratio against those of similar companies.
However Athira Pharma's short interest can also be evaluated against the total number of Athira Pharma shares, or, against the total number of tradable Athira Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Athira Pharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Athira Pharma shares in existence, roughly 20 shares are currently held short) or 0.0247% of the tradable shares (for every 100,000 tradable Athira Pharma shares, roughly 25 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Athira Pharma.
Find out more about how you can short Athira Pharma stock.
We're not expecting Athira Pharma to pay a dividend over the next 12 months.
Athira Pharma, Inc., a clinical-stage biopharmaceutical company, develops small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in various clinical trials for the treatment of Alzheimer's and Parkinson's diseases. The company also develops product candidates, which are in preclinical stage, including ATH-1019 for depression; and ATH-1018 for peripheral neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is based in Seattle, Washington.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.